SciSparc (SPRC) announced that NeuroThera Labs, a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders in which SciSparc holds a controlling interest of approximately 75%, has advanced its collaboration with Clearmind Medicine (CMND) by filing an Israeli patent application for an innovative combination therapy of 5-methoxy-2-aminoindane and N-Acylethanolamines, such as Palmitoylethanolamide, targeting depression. The patent application results from the ongoing collaboration between Neurothera and Clearmind Medicine. This therapy targets depression treatment using the combination of MEAI and PEA. This new filing further expands the joint intellectual property portfolio developed through the collaboration. To date, 13 patents have been filed through the collaboration, focusing on MEAI and N-Acylethanolamines combinations for conditions such as alcohol use disorder, cocaine addiction, obesity and weight loss, and depression.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRC:
- SciSparc Ltd. Releases Interim Financial Results for H1 2025
- Clearmind Medicine files Israeli patent for depression treatment
- N2OFF completes merger with MitoCareX Bio
- SciSparc’s Promising Clinical Study on SCI-210 for Autism Spectrum Disorder
- SciSparc’s SCI-110 Study: A Potential Game-Changer for Tourette Syndrome